Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05375760 · ClinicalTrials.gov registry record · Phase 2
A Randomized, Open-label, Dose-ranging Study in Adults and Pediatric Individuals ≥ 12 Years of Age to Assess the Safety, Immunogenicity, Pharmacokinetics, and Pharmacodynamics of AZD7442, for Pre-exposure Prophylaxis of COVID-19
A Phase 2 study, sponsored by AstraZeneca.
- Terminated
- Registry status
- Phase 2
- Development phase
- 251
- Enrollment target
NCT05375760 is a Phase 2 study that was terminated before completion, run by AstraZeneca. The registered enrollment target is 251 participants.
The verdict
NCT05375760, a Phase 2 study, was terminated before completion, sponsored by AstraZeneca.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 251 participants
- Enrollment target
Study Summary
A Phase II Randomized, Open-label, Multicenter, Dose-ranging Study in Adults and Pediatric Individuals ≥ 12 years of Age to Assess the Safety, Immunogenicity, Pharmacokinetics, and Pharmacodynamics of AZD7442, a Combination Product of Two Monoclonal Antibodies (Tixagevimab and Cilgavimab), for Pre-exposure Prophylaxis of COVID-19
Interventions
- BIOLOGICAL AZD7442 (tixagevimab [AZD8895] + cilgavimab [AZD1061])
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 251 participants |
| Start Date | 2022-06-09 |
| Est. Completion | 2023-10-04 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05375760
The ClinicalTrials.gov registry entry for NCT05375760 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 251 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which AZD7442 (tixagevimab [AZD8895] + cilgavimab [AZD1061]) is the first listed.
NCT05375760 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05375760 about?
NCT05375760 is a clinical study titled "A Randomized, Open-label, Dose-ranging Study in Adults and Pediatric Individuals ≥ 12 Years of Age to Assess the Safety, Immunogenicity, Pharmacokinetics, and Pharmacodynamics of AZD7442, for Pre-exposure Prophylaxis of COVID-19". A Phase II Randomized, Open-label, Multicenter, Dose-ranging Study in Adults and Pediatric Individuals ≥ 12 years of Age to Assess the Safety, Immunogenicity, Pharmacokinetics, and Pharmacodynamics of AZD7442, a Combination Product of Two Monoclonal Antibodies (Tixagevimab and Cilgavimab), for Pre-e...
What is the current status of trial NCT05375760?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 251 participants. The study started on 2022-06-09. Estimated completion is 2023-10-04.
What interventions are being tested in trial NCT05375760?
The interventions under investigation include: AZD7442 (tixagevimab [AZD8895] + cilgavimab [AZD1061]) (BIOLOGICAL).
Who is sponsoring clinical trial NCT05375760?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.